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Abstract
Tumor genetics guides patient selection for many new therapies, and cell culture studies have 
demonstrated that specific mutations can promote metabolic phenotypes. However, whether tissue 
context defines cancer dependence on specific metabolic pathways is unknown. Kras activation 
and Trp53 deletion in the pancreas or the lung result in pancreatic ductal adenocarinoma (PDAC) 
or non-small cell lung carcinoma (NSCLC) respectively, but despite the same initiating events, 
these tumors utilize branched-chain amino acids (BCAAs) differently. NSCLC tumors incorporate 
free BCAAs into tissue protein and use BCAAs as a nitrogen source while PDAC tumors have 
decreased BCAA uptake. These differences are reflected in expression levels of BCAA catabolic 
enzymes in both mice and humans. Loss of Bcat1 and Bcat2, the enzymes responsible for BCAA 
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utilization, impairs NSCLC tumor formation, but these enzymes are not required for PDAC tumor 
formation, arguing that tissue-of-origin is an important determinant of how cancers satisfy their 
metabolic requirements.
Main Text
The development of new cancer therapeutics relies on underlying genetic features to identify 
sensitive patients (1). Mutations in both KRAS and TP53 are common genetic events found 
in tumors arising from many tissues and cancers with these mutations are often difficult to 
treat (2, 3). These genetic events, as well as others associated with cancer, contribute to the 
metabolic changes that support biomass accumulation and cancer cell proliferation (4). 
Oncogenic RAS signaling increases glucose and glutamine consumption to support anabolic 
processes including nucleotide, lipid and non-essential amino acid biosynthesis and can also 
drive extracellular protein and lipid scavenging (5). TP53 mutations increase glucose 
consumption and glycolytic flux, while inactivation of TP53 renders cancer cells more 
dependent on serine uptake and metabolism (6).
KRAS and TP53 mutations are found in most human pancreatic tumors (7) and are also 
common in lung adenocarcinoma (8). How mutant KRAS or disruption of TP53 affect 
cancer metabolism is based on cell culture studies in defined medium, although in vivo 
nutrient availability varies widely between tissues and vasculature changes can limit nutrient 
access within tumors (9, 10). The inability to model these differences in culture has therefore 
limited understanding of how tissue-of-origin influences tumor metabolism (11). 
Furthermore, environment can influence metabolic phenotypes in vitro (12–14), and 
metabolic dependencies in vivo can differ from those found in vitro (15). Metabolic 
differences between tumor types may also result from cell-autonomous effects, and tumor 
metabolic gene expression more closely resembles that of its tissue-of-origin than that of 
other tumors (16). The same oncogenic driver can also cause different metabolic phenotypes 
in lung and liver tumors (17). This raises the possibility that tumor type is a major 
determinant of some tumor metabolic dependencies in vivo.
Elevated plasma BCAA levels are found in early PDAC, but not in NSCLC, even when the 
tumors are initiated by the same genetic events (18). To confirm that tumor tissue-of-origin 
influences whole-body BCAA metabolism, we utilized LSL–KrasG12D/+; Trp53flox/flox (KP) 
mice. We crossed KP mice to mice harboring a Cre-recombinase allele driven by a Pdx-1 
promoter (KP−/−C model) (19) or delivered viral Cre to the lungs of these mice (20) to 
generate models of PDAC and NSCLC respectively. Consistent with prior reports (18), mice 
with early PDAC have increased levels of plasma BCAAs while mice with early NSCLC 
exhibit decreased plasma BCAA levels (figs. S1, A–D). When cells derived from these 
tumors are implanted subcutaneously into syngeneic hosts, tumors derived from PDAC cells 
did not affect plasma BCAA levels (fig. S1E) (18), while tumors derived from NSCLC cells 
led to decreased plasma BCAAs (fig. S1F). These results suggest that tumor formation from 
NSCLC cells can cause depletion of circulating BCAAs.
To trace tissue-specific differences in BCAA metabolism in animals with pancreatic or lung 
tumors, mice were fed an amino acid defined diet in which 20% of leucine and valine 
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were 13C-labeled. All groups of mice exhibited similar levels of plasma 13C-BCAA 
enrichment after one-week exposure to labeled diets (figs. S2, A and B). While PDAC 
tumors contained slightly decreased free BCAAs relative to normal pancreas, NSCLC 
tumors displayed a significant increase in labeled free BCAAs compared to normal lung 
(Fig. 1A and figs. S2, C and D). Importantly, these differences are not a reflection of 
different amino acid compositions of normal or tumor tissue in either the PDAC or NSCLC 
models (fig. S3). Because BCAAs are essential amino acids that animals cannot synthesize 
de novo (21), these results suggest that unlike PDAC tumors, NSCLC tumors display 
enhanced BCAA uptake.
BCAAs have several potential metabolic fates in tissues (Fig. 1B). They can be directly 
incorporated into protein or reversibly transaminated by branched-chain amino acid 
transaminase (Bcat) to produce branched-chain α-ketoacids (BCKAs) and glutamate. 
BCKAs can regenerate BCAAs, be secreted, or be oxidatively decarboxylated by the 
branched-chain keto-acid dehydrogenase (Bckdh) complex to allow further oxidation of the 
carbon skeleton (21). In agreement with increased BCAA uptake in NSCLC tumors, lung 
tumors displayed increased labeled BCAA incorporation into protein compared to normal 
lung, while PDAC tumors incorporated less labeled BCAAs relative to normal pancreas 
(Fig. 1C and figs. S2, E and F). Analysis of metabolites derived from BCAA catabolism 
revealed that NSCLC tumors also had more labeled α-ketoisocaproate (KIC), the leucine-
derived BCKA, while no change was observed in levels of this labeled metabolite in PDAC 
tumors (Fig. 1D and fig. S2G). No other differences in labeled BCAA catabolite levels were 
observed in NSCLC compared to normal tissues, but PDAC tumors showed decreased 
labeling of the tricarboxylic acid (TCA) cycle intermediate citrate relative to normal 
pancreas from labeled BCAAs (Fig. 1E and figs. S2, G–I). This is consistent with recent 
work demonstrating minimal catabolism of BCAAs to TCA intermediates in proliferating 
cells (22). We then explored whether excess KIC may be excreted by NSCLC tumors for 
further metabolism by other tissues such as liver, which has limited Bcat, but high Bckdh 
activity (21, 23). Consistent with this hypothesis, we observe increased labeling of 
downstream leucine metabolites in the livers of mice with lung tumors (fig. S4). Taken 
together, these data suggest that BCAA uptake and transamination, but not their subsequent 
catabolism, may provide a benefit to NSCLC tumors, potentially by acting as a source of 
nitrogen.
To examine whether NSCLC tumors, but not PDAC tumors, use BCAAs as a source of 
nitrogen, we fed mice a modified amino acid diet where 50% of leucine was labeled 
with 15N, allowing the fate of leucine-derived nitrogen to be traced (Fig. 2A). In agreement 
with 13C-tracing, mice with PDAC demonstrated no differences in free 15N-labeled leucine 
in tumors compared to control pancreas (fig. S5A), and had less 15N incorporation into other 
amino acids (fig. S5B). In contrast, increased levels of 15N-leucine were found in NSCLC 
tumors compared to normal lung (fig. S5C) with decreased plasma enrichment of 15N-
leucine in mice with NSCLC tumors (Fig. 2B and fig. S5D). A relative increase in 15N-
labeling of non-essential amino acids, as well as valine and isoleucine, was observed in both 
the free and tissue-protein amino acid pools of NSCLC compared to control lung (Fig. 2C 
and figs. S5, C and E). Given the reduced plasma enrichment transamination mediated by 
Bcat isoforms is active in NSCLC tumor tissue. Evidence for increased BCAA 
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transamination in NSCLC compared to PDAC cells is also evident in vitro across a range of 
glutamine concentrations, however tissue culture does not recapitulate the same phenotypes 
observed in tumors (fig. S6). Downstream of non-essential amino acid biosynthesis, this 
nitrogen can also be used to generate nucleotides, primarily if aspartate is synthesized de 
novo in these tumors. Consistent with this possibility, we find increased incorporation 
of 15N-label in both aspartate and nucleotides (Figs. 2, C and D and fig. S5E). In some 
contexts, aspartate production is limiting for nucleotide biosynthesis and proliferation (24, 
25), indicating that BCAA metabolism may be important for tumor growth.
To test whether gene expression differences might contribute to differential BCAA 
metabolism, we used quantitative RT-PCR to analyze mRNA levels in NSCLC and PDAC 
tumors compared to their respective normal tissues. Consistent with increased BCAA uptake 
and KIC generation in NSCLC tumors, these tumors displayed increased expression of the 
primary BCAA transporter Slc7a5 (also called the neutral amino acid transporter Lat1) and 
increased levels of Bcat2 and Bckdh (Figs. 3, A, C and D). In contrast, PDAC exhibited 
decreased expression of these genes relative to normal pancreas (Figs. 3, B–D). Importantly, 
we also observed increased inhibitory phosphorylation of the Bckdh complex in lung tumors 
(Figs. 3, C and D). Bcat expression enables utilization of BCAAs as a source of nitrogen by 
lung tumors, and inhibition of Bckdh prevents further catabolism of these amino acids.
The expression changes observed in PDAC are not unique to this model, as the related KPC 
mouse model (26), which is initiated by a point mutation in Trp53, showed similar changes 
in gene expression (fig. S7A). Furthermore, these decreases in gene expression do not 
appear to be a consequence of the relative decrease in cancer cellularity of PDAC tumors 
(7), as sorted pancreatic cancer cells showed similar expression of genes involved in 
proximal BCAA catabolism relative to whole tumor extracts (fig. S7B). In further agreement 
with neither lung nor pancreatic cancers showing evidence of downstream BCAA-carbon 
oxidation, the expression of enzymes from this pathway was not markedly different in either 
of these cancers (figs. S7, C and D). In contrast, glycolytic gene expression was increased in 
both tumor types (figs. S7, E and F), which is consistent with known increases in glycolysis 
in each tumor type (27–29). Finally, to relate these data to tissue-of-origin, we performed 
principal component and clustering analyses, which demonstrated segregation of each tumor 
with the normal tissue from which it arose (figs. S7, G and H).
To ascertain whether similar changes in gene expression were also found in human cancers, 
we examined expression of BCAA catabolic enzymes in NSCLC and PDAC relative to their 
respective normal tissues in publically available data sets (30). Consistent with our 
observations in mice, human NSCLC had increased expression of SLC7A5, BCAT, and 
BCKDH, while expression of BCAA catabolism pathway enzymes was decreased in human 
PDAC (P < 0.0001 for the pathway) (Fig. 3E and tables S1 and S2). The distinct expression 
patterns for each tumor type were highly correlated across multiple data sets (fig. S7I and 
tables S3–6). Interestingly, the similarity between human NSCLC and the mouse model of 
NSCLC was observed despite KRAS and TP53 mutations occurring in less than 50% of 
human tumors (8) and similar expression patterns were also seen in squamous cell lung 
cancer (fig. S7I and table S6), further supporting the notion that tissue-of-origin can dictate 
metabolic phenotype.
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The increased contribution of plasma BCAAs to biomass in NSCLC tumors suggests that 
these tumors may rely on BCAA metabolism for growth. To test this possibility, we used 
CRISPR-Cas9 mediated genome editing to disrupt exon sequences present in both the Bcat1 
(cytosolic) and the Bcat2 (mitochondrial) isoforms (fig. S8A) in cancer cell lines derived 
from KP mice with NSCLC (Bcat null Clones A and B) or PDAC (Bcat null) (fig. S8B). 
Expression analysis and 15N-leucine tracing studies confirmed functional deletion of Bcat in 
both the NSCLC and PDAC cancer cells (figs. S8, C–F). Despite loss of both Bcat isoforms, 
these cells proliferate at a rate that is similar to the parental and vector control infected cell 
lines in vitro (Figs. 4, A and B). When Bcat null NSCLC cells were implanted 
subcutaneously in vivo, however, the ability of these cells to form tumors was significantly 
impaired, and one clone failed to produce tumors (Fig. 4C and fig. S8G). In contrast, Bcat 
null PDAC cells implanted subcutaneously generated tumors (Fig. 4D and fig. S8H). 
Additionally, orthotopic transplantation of NSCLC Bcat null cells failed to form lung tumors 
(Fig. 4E), while PDAC Bcat null cells formed tumors in the pancreas (Fig. 4F). Unlike 
subcutaneously implanted PDAC Bcat knockout cells, these cells formed smaller tumors in 
the pancreas than control cells (fig. S8I). Taken together, these data suggest that while KP 
lung tumors require Bcat activity for growth, this enzyme activity is dispensable for KP 
pancreas tumor formation, although PDAC tumor growth may be aided by Bcat activity in 
some tissue environments.
Proliferating cells need to acquire amino acids, both to make protein and as source of 
nitrogen for nucleotide and non-essential amino acid synthesis. Prior work has shown that 
macropinocytosis plays a role in filling this requirement in mutant RAS-driven PDAC 
tumors and cells (12, 14, 31). The data presented here argue that this process might be less 
active in mutant Ras transformed NSCLC tumors that acquire nitrogen in part from free 
BCAAs. Indeed, we observed less macropinocytosis in cells derived from mouse NSCLC 
relative to mouse PDAC cells (fig. S9). The decreased reliance of PDAC on free BCAAs 
however, does not necessarily imply that uptake of these amino acids would be toxic for this 
cancer. Overexpressing Slc7a5 in PDAC cells is sufficient to increase leucine uptake (figs. 
S10, A and B), but has minimal effects on proliferation in vitro (fig. S10C) or tumor growth 
in vivo (figs. S10, D and E).
A role for free BCAAs in supplying nitrogen to lung cancers is intriguing in light of recent 
studies in glioblastoma and NSCLC indicating that glutamine, which is the most abundant 
plasma amino acid and serves as the major free amino acid substrate for nitrogen and carbon 
in culture (32), contributes less to tumor metabolism in vivo (33, 34). Indeed, glucose-
tracing studies in humans and mice demonstrate that glutamine is net synthesized from 
glucose (15, 33–37), and alternative sources of nitrogen are required to support glutamine 
production. Thus, in these contexts, extraction of nitrogen from BCAAs for de novo amino 
acid and nucleotide biosynthesis in vivo may explain how lung tumors satisfy their nitrogen 
requirements. Consistent with this possibility, BCAT1 expression is known to be important 
for glioblastoma growth (38), suggesting that tumors arising in tissues other than the lung 
may also utilize BCAAs as a source of nitrogen. Multiple factors including local 
environment, tumor cell-of-origin, and genetic mutations can lead to convergent metabolic 
adaptations in disparate tumor types.
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Elevations in plasma BCAA levels are associated with early PDAC and result from increased 
tissue protein breakdown (18). The finding that PDAC tumors have decreased utilization of 
circulating BCAAs contributes to this phenotype as well. In contrast, NSCLC tumors 
actively utilize BCAAs leading to plasma BCAA depletions, particularly since the liver does 
not regulate levels of these amino acids (23). Many patients with PDAC and NSCLC tumors 
develop cachexia with end-stage disease (39). Our findings suggest that differential use of 
amino acids by tumors and the resulting impact on whole body metabolism might play a role 
in the initiation and natural history of cachexia. In addition, as personalized medicine plays a 
larger role in the clinical management of cancer, it will be critical to understand how cell-of-
origin and tissue environment interact with genetic events to influence metabolic 
dependencies of tumors and select the right treatment approaches for patients.
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Fig. 1. Mice with NSCLC display increased BCAA uptake and metabolism
(A and C–E) Mice were fed 13C-BCAA containing diet for seven days. (A) Relative ion 
counts by LC-MS analysis of fully-labeled, free BCAAs in tumors from PDAC and NSCLC 
mice and normal tissues from their respective control mice. Data are presented as mean ± 
SEM. N = 4 control and N = 4 PDAC; N = 4 control and N = 4 NSCLC. (B) Diagram of the 
leucine catabolic pathway. Red labels indicate metabolites measured by mass spectrometry. 
Blue circles indicate 13C-labeled carbons. KIC = α-ketoisocaproate. (C) Relative ion counts 
by GC-MS analysis of fully-labeled BCAAs from protein acid hydrolysates of tumors from 
PDAC and NSCLC mice and normal tissues from their respective control mice. Data are 
presented as mean ± SEM. N = 4 control and N = 4 PDAC; N = 4 control and N = 4 
NSCLC. (D) Relative ion counts by LC-MS analysis of fully-labeled KIC in tumors from 
PDAC and NSCLC mice and normal tissues from their respective control mice. Data are 
presented as mean ± SEM. N = 4 control and N = 4 PDAC; N = 4 control and N = 4 
NSCLC. (E) Citrate M+2 labeling (%) from [U-13C]-leucine by GC-MS analysis in tumors 
from PDAC and NSCLC mice and normal tissues from their respective control mice. Data 
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are presented as mean ± SEM. N = 4 control and N = 4 PDAC; N = 4 control and N = 4 
NSCLC. Two-tailed t test was used for all comparisons between two groups. * P<0.05, ** 
P<0.01, *** P<0.001
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Fig. 2. BCAA-Derived Nitrogen Supports Non-Essential Amino Acid and DNA Synthesis in 
NSCLC tumors
(A) Diagram of leucine transamination by Branched-chain amino acid transferase (Bcat) and 
nitrogen (green circles) fate after transamination. (B–D) NSCLC mice were fed 15N-leucine 
containing diet for six days. (B) Relative ion counts by GC-MS analysis of M+1 labeled 
amino acids in plasma of control and NSCLC mice. Data are presented as mean ± SEM. N = 
5 control and N = 6 NSCLC. (C) Relative ion counts by GC-MS analysis of M+1 labeled 
amino acids from protein acid hydrolysates of control mouse lung tissue and NSCLC mouse 
tumors. Data are presented as mean ± SEM. N = 6 control and N = 6 NSCLC. (D) M+1 
labeling (%) from 15N-leucine of deoxynucleic acids from nucleic acid digest of control 
mouse lung tissue and NSCLC mouse tumors. Data are presented as mean ± SEM. N = 6 
control and N = 6 NSCLC. Two-tailed t test was used for all comparisons between two 
groups. * P<0.05, ** P<0.01, *** P<0.001
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Fig. 3. Gene expression in both mouse and human tumors reflects tumor tissue-specific BCAA 
metabolism
(A) Relative Expression of BCAA metabolic pathway genes in normal lung and NSCLC 
tumors from KP mice. Data are presented as mean ± SEM. N = 6 control and N = 6 NSCLC. 
(B) Relative expression of BCAA metabolic pathway genes in normal pancreas and PDAC 
tumors from KP mice. Data are presented as mean ± SEM. N = 7 control and N = 5 PDAC. 
(C) Immunoblots of proteins involved in BCAA metabolism in representative normal lung 
and NSCLC tumors (left) and representative normal pancreas and PDAC tumors (right) from 
KP mice. (D) Quantification of (C). Data are presented as mean ± SEM. N = 6 control and N 
= 6 NSCLC; N = 4 control and N = 4 PDAC. (E) Comparison of BCAA metabolic pathway 
gene expression in human NSCLC and PDAC tumors relative to their adjacent paired normal 
tissues. Overall expression of BCAA metabolism genes is significantly decreased in PDAC 
(P<0.0001). Two-tailed t test was used for all comparisons between two groups unless 
otherwise stated. * P<0.05, ** P<0.01, *** P<0.001
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Fig. 4. Branched-chain amino acid transaminase (Bcat) activity is required for NSCLC tumor 
growth
(A) Doubling time of parental, control CRISPR-Cas9 vector infected (pLenti), and NSCLC 
Bcat null cell lines in vitro. Data are presented as mean ± SEM. N = 3 per group. 
Representative experiment from ≥ 2 repeats. (B) Doubling time of parental, control 
CRISPR-Cas9 vector infected and PDAC Bcat null cell lines in vitro. Data are presented as 
mean ± SEM. N = 3 per group. Representative experiment from ≥ 2 repeats. (C) Estimated 
tumor volume (mm3) of subcutaneous allograft of control infected and Bcat null syngenic 
NSCLC cell lines into C57BL/6J mice. Data are presented as mean ± SEM. N = 6 per group. 
Two-way repeated measures ANOVA used for comparison between groups. (D) Estimated 
tumor volume (mm3) of subcutaneous allograft of control infected and Bcat null syngenic 
PDAC cell lines into C57BL/6J mice. Data are presented as mean ± SEM. N = 5 pLenti 
control and N = 6 Bcat null. Two-way repeated measures ANOVA used for comparison 
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between groups. (E) Lung orthotopic allograft of control infected and Bcat null syngenic 
NSCLC cell lines into C57BL/6J mice. N = 23 vector control and N = 13 Bcat null Clone A. 
(F) Pancreatic orthotopic allograft of control infected and Bcat null syngenic PDAC cell 
lines into C57BL/6J mice. N = 8 per group. * P<0.05, ** P<0.01, *** P<0.001.
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